Liver cancer : nature.com subject feedshttps://www.nature.com/subjects/liver-cancer.atom2024-03-29T00:17:16+00:00HCC genomic landscape in Chinese individualshttps://www.nature.com/articles/s41575-024-00924-12024-03-22T00:00:00+00:002024-03-22T00:00:00+00:00Eleni KotsilitiEnhancing diagnostic precision in liver lesion analysis using a deep learning-based system: opportunities and challengeshttps://www.nature.com/articles/s41571-024-00887-x2024-03-22T00:00:00+00:002024-03-22T00:00:00+00:00Jeong Min Lee et al.Cancer cell genetics shaping of the tumor microenvironment reveals myeloid cell-centric exploitable vulnerabilities in hepatocellular carcinomahttps://www.nature.com/articles/s41467-024-46835-22024-03-22T00:00:00+00:002024-03-22T00:00:00+00:00Christel F. A. Ramirez et al.Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implicationshttps://www.nature.com/articles/s41417-024-00764-w2024-03-18T00:00:00+00:002024-03-18T00:00:00+00:00Fatema Safri et al.METTL3 and METTL14-mediated N6-methyladenosine modification of SREBF2-AS1 facilitates hepatocellular carcinoma progression and sorafenib resistance through DNA demethylation of SREBF2https://www.nature.com/articles/s41598-024-55932-72024-03-14T00:00:00+00:002024-03-14T00:00:00+00:00Xianjian Wu et al.The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trialhttps://www.nature.com/articles/s41467-024-46542-y2024-03-11T00:00:00+00:002024-03-11T00:00:00+00:00David Hsiehchen et al.Catastrophic conformityhttps://www.nature.com/articles/s41568-024-00678-72024-03-01T00:00:00+00:002024-03-01T00:00:00+00:00Gabrielle BrewerReversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockadehttps://www.nature.com/articles/s41598-024-55593-62024-03-01T00:00:00+00:002024-03-01T00:00:00+00:00S. K. Daniel et al.SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosishttps://www.nature.com/articles/s41698-024-00545-62024-03-01T00:00:00+00:002024-03-01T00:00:00+00:00Youpeng Wang et al.The transcription factor ChREBP Orchestrates liver carcinogenesis by coordinating the PI3K/AKT signaling and cancer metabolismhttps://www.nature.com/articles/s41467-024-45548-w2024-02-29T00:00:00+00:002024-02-29T00:00:00+00:00Emmanuel Benichou et al.Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinomahttps://www.nature.com/articles/s41571-024-00868-02024-02-29T00:00:00+00:002024-02-29T00:00:00+00:00Josep M. Llovet et al.Circulating miRNA’s biomarkers for early detection of hepatocellular carcinoma in Egyptian patients based on machine learning algorithmshttps://www.nature.com/articles/s41598-024-54795-22024-02-29T00:00:00+00:002024-02-29T00:00:00+00:00Gehad Ismail Sayed et al.Targeting the IRE1α-XBP1s axis confers selective vulnerability in hepatocellular carcinoma with activated Wnt signalinghttps://www.nature.com/articles/s41388-024-02988-42024-02-28T00:00:00+00:002024-02-28T00:00:00+00:00Tingting Zhang et al.Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinomahttps://www.nature.com/articles/s41467-024-46118-w2024-02-26T00:00:00+00:002024-02-26T00:00:00+00:00Meng He et al.Cryptogenic non-cirrhotic HCC: Clinical, prognostic and immunologic aspects of an emerging HCC etiologyhttps://www.nature.com/articles/s41598-024-52884-w2024-02-21T00:00:00+00:002024-02-21T00:00:00+00:00Boris J. B. Beudeker et al.Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysishttps://www.nature.com/articles/s41598-024-54945-62024-02-21T00:00:00+00:002024-02-21T00:00:00+00:00Litao Huang et al.Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trialhttps://www.nature.com/articles/s41591-024-02824-y2024-02-19T00:00:00+00:002024-02-19T00:00:00+00:00Hyung-Don Kim et al.Child–Pugh grade deterioration stratified by the etiology after transcatheter arterial chemoembolization as initial treatment for hepatocellular carcinomahttps://www.nature.com/articles/s41598-024-53709-62024-02-14T00:00:00+00:002024-02-14T00:00:00+00:00Kengo Yoshitomi et al.Deep whole-genome analysis of 494 hepatocellular carcinomashttps://www.nature.com/articles/s41586-024-07054-32024-02-14T00:00:00+00:002024-02-14T00:00:00+00:00Lei Chen et al.Crosstalk between endothelial progenitor cells and HCC through periostin/CCL2/CD36 supports formation of the pro-metastatic microenvironment in HCChttps://www.nature.com/articles/s41388-024-02960-22024-02-13T00:00:00+00:002024-02-13T00:00:00+00:00Tuo Deng et al.HKDC1 promotes tumor immune evasion in hepatocellular carcinoma by coupling cytoskeleton to STAT1 activation and PD-L1 expressionhttps://www.nature.com/articles/s41467-024-45712-22024-02-13T00:00:00+00:002024-02-13T00:00:00+00:00Yi Zhang et al.Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrencehttps://www.nature.com/articles/s41575-024-00904-52024-02-12T00:00:00+00:002024-02-12T00:00:00+00:00Jordan HindsonA multicenter clinical AI system study for detection and diagnosis of focal liver lesionshttps://www.nature.com/articles/s41467-024-45325-92024-02-07T00:00:00+00:002024-02-07T00:00:00+00:00Hanning Ying et al.Adjuvant sintilimab effective in high-risk HCChttps://www.nature.com/articles/s41571-024-00865-32024-02-05T00:00:00+00:002024-02-05T00:00:00+00:00Peter SidawayTargeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancerhttps://www.nature.com/articles/s41419-024-06493-02024-02-03T00:00:00+00:002024-02-03T00:00:00+00:00Yunong Xie et al.Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinomahttps://www.nature.com/articles/s41467-024-45215-02024-02-02T00:00:00+00:002024-02-02T00:00:00+00:00Chunxiao Liu et al.Role of UPF1 in lncRNA-HEIH regulation for hepatocellular carcinoma therapyhttps://www.nature.com/articles/s12276-024-01158-62024-02-01T00:00:00+00:002024-02-01T00:00:00+00:00Hyunho Cha et al.Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liverhttps://www.nature.com/articles/s41586-023-06991-92024-01-31T00:00:00+00:002024-01-31T00:00:00+00:00Weiguo Fan et al.Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinomahttps://www.nature.com/articles/s41598-024-52237-72024-01-30T00:00:00+00:002024-01-30T00:00:00+00:00Nicholas J. G. Webster et al.DNA polymerase beta connects tumorigenicity with the circadian clock in liver cancer through the epigenetic demethylation of Per1https://www.nature.com/articles/s41419-024-06462-72024-01-20T00:00:00+00:002024-01-20T00:00:00+00:00Siyu Chen et al.